Find Print
0 Find synonyms

Find synonyms Find exact match

What's new in dermatology
Official reprint from UpToDate® ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
What's new in dermatology
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Apr 2017. | This topic last updated: May 09, 2017.

The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.


Dupilumab for moderate to severe atopic dermatitis (April 2017)

Dupilumab is an interleukin-4 receptor alpha antagonist being evaluated in atopic dermatitis. In two 16-week clinical trials (SOLO1 and SOLO2), dupilumab was more effective than placebo in improving the signs and symptoms of atopic dermatitis [1]. Based on these results, the US Food and Drug Administration has approved dupilumab for the treatment of adult patients with moderate to severe atopic dermatitis not adequately controlled with topical prescription therapies [2]. While the role for dupilumab is still evolving, it appears to be a reasonable option for adult patients with severe disease who have failed other systemic therapies. (See "Treatment of atopic dermatitis (eczema)", section on 'Dupilumab'.)

Nemolizumab for atopic dermatitis (March 2017)

Some patients with atopic dermatitis do not experience disease control with topical treatments. In a phase 2 trial, 264 patients with moderate to severe atopic dermatitis not controlled by topical corticosteroids or topical calcineurin inhibitors were randomly assigned to monthly subcutaneous nemolizumab, an investigational humanized monoclonal antibody against interleukin-31, at three different doses or to placebo [3]. At 12 weeks, pruritus was reduced by 44, 60, and 63 percent, in the low, medium, and high dose groups, respectively, versus 21 percent in the placebo group. However, nemolizumab did not reduce the body surface area affected by atopic dermatitis. Adverse effects occurred in approximately 70 percent of patients in all study groups and were generally mild, with the most frequent being exacerbation of atopic dermatitis and respiratory tract infections. Although nemolizumab appears to be a promising treatment for pruritus associated with atopic dermatitis, larger studies of longer durations are needed to confirm its efficacy and safety. (See "Treatment of atopic dermatitis (eczema)", section on 'Nemolizumab'.)

Topical crisaborole for atopic dermatitis (December 2016)

A topical preparation containing 2% crisaborole, an investigational boron-based, small-molecule, phosphodiesterase-4 inhibitor, was approved by the US Food and Drug Administration in December 2016 for the treatment of mild to moderate atopic dermatitis in patients two years of age and older [4]. In four-week clinical trials, topical crisaborole was more effective than placebo in reducing pruritus, skin inflammation, excoriation, and lichenification. However, trials comparing topical crisaborole with other topical treatments for atopic dermatitis are lacking. (See "Treatment of atopic dermatitis (eczema)", section on 'Crisaborole'.)

Investigational topical tofacitinib for atopic dermatitis (November 2016)

Tofacitinib is a small-molecule JAK kinase inhibitor that is currently available as an oral therapy for rheumatoid arthritis. An investigational topical preparation was compared with placebo in a randomized trial of 69 adult patients with mild to moderate atopic dermatitis, treated for four weeks [5]. Compared with those receiving placebo, subjects receiving tofacitinib showed greater improvements in eczema area and severity scores, were more likely to be assessed by physicians as clear or almost clear, and tolerated the drug well. Larger studies of longer duration are needed to evaluate long-term efficacy and safety. (See "Treatment of atopic dermatitis (eczema)", section on 'Tofacitinib'.)

Persistence of pediatric atopic dermatitis (November 2016)

Atopic dermatitis (AD) is a chronic disease with a highly variable course. Although most children are thought to “outgrow” it before adolescence, little is known about the factors associated with its persistence into adulthood. A meta-analysis including over 110,000 subjects found that 20 percent of children with AD had persistent disease eight years after the diagnosis, and less than 5 percent had persistent disease 20 years later [6]. Children who developed AD before two years of age had a much lower risk of persistent disease than those who developed AD later in childhood or during adolescence. Other predictors of persistent AD were severity and duration of AD and female sex, whereas hypersensitivity to one or more allergens at disease onset did not seem to influence the persistence of disease. (See "Pathogenesis, clinical manifestations, and diagnosis of atopic dermatitis (eczema)", section on 'Clinical course and complications'.)


Doxycycline versus prednisolone for the initial treatment of bullous pemphigoid (March 2017)

Tetracyclines have a long history of use for the management of bullous pemphigoid; however, high-quality data on the efficacy of tetracyclines are limited. In a multicenter randomized trial including approximately 250 patients receiving initial treatment for bullous pemphigoid, doxycycline was noninferior to oral prednisolone, with fewer associated severe, life-threatening, or fatal events [7]. Although topical and systemic corticosteroids remain our standard first-line treatments for bullous pemphigoid, these results support doxycycline as an alternative treatment. Doxycycline may be particularly useful when topical corticosteroid therapy is impractical and systemic corticosteroid therapy is likely to be poorly tolerated. (See "Management and prognosis of bullous pemphigoid", section on 'Antibiotics and nicotinamide'.)

Management of microvascular damage in systemic sclerosis (December 2016)

Vasoactive drugs are used for systemic sclerosis (SSc) patients with severe Raynaud phenomenon (RP) and digital ulcers. For prevention of recurrent digital ulcers, there may be a benefit from combination therapy with intravenous iloprost and bosentan. In a prospective observational study with 30 SSc patients receiving intravenous iloprost for severe secondary RP, half of the patients were also given bosentan following the development of digital ulcers or pulmonary arterial hypertension [8]. After four years of follow-up, the iloprost plus bosentan group showed evidence of a significant improvement in digital microvasculature structure and function, which also corresponded with a significant reduction in the incidence of new digital ulcers. This limited study needs confirmation but suggests that combination therapy may be helpful in complex SSc patients with recurrent digital ulcers. (See "Treatment of the Raynaud phenomenon resistant to initial therapy", section on 'Recurrent digital ulcers in systemic sclerosis'.)

Tofacitinib for alopecia areata (December 2016)

Support is increasing for the use of tofacitinib, a small molecule selective Janus kinase 1/3 inhibitor, for alopecia areata. A retrospective study of long-term treatment with tofacitinib (with or without adjuvant prednisone) in 90 adults with severe alopecia areata (at least 40 percent scalp hair loss, alopecia totalis, or alopecia universalis) found that over one-half of the 65 patients with a duration of the current disease episode of ≤10 years achieved greater than 50 percent improvement in the Severity of Alopecia Tool [SALT] score, without serious adverse effects [9]. Although these findings suggest benefit of tofacitinib for alopecia areata, controlled trials are needed to confirm efficacy and safety. (See "Management of alopecia areata", section on 'Janus kinase inhibitors'.)


Guidelines on diagnosis and treatment of leishmaniasis (January 2017)

Guidelines on the management of leishmaniasis in North America were published by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) in December 2016 [10]. They emphasize use of multiple diagnostic tools to maximize diagnostic likelihood and submission of relevant specimens to a reference laboratory for parasite species identification. For suspected cutaneous leishmaniasis (CL), a full-thickness skin biopsy from a clean, active-appearing ulcer is recommended; for patients with mucocutaneous leishmaniasis (ML), biopsy specimens should be obtained by an otolaryngologist. For suspected visceral leishmaniasis (VL), bone marrow aspirate is the preferred sample; in addition, serum should be tested for antileishmanial antibodies. The treatment approach to CL depends on several factors, including the extent of disease, the infecting parasite species, and the presence of immunocompromising conditions. For VL, liposomal amphotericin B is the preferred treatment; miltefosine, pentavalent antimonials, and other forms of amphotericin are alternatives. (See "Cutaneous leishmaniasis: Clinical manifestations and diagnosis" and "Cutaneous leishmaniasis: Treatment" and "Visceral leishmaniasis: Clinical manifestations and diagnosis" and "Visceral leishmaniasis: Treatment".)


Brodalumab for moderate to severe plaque psoriasis (February 2017)

Brodalumab, an anti-IL-17 receptor A monoclonal antibody, is a new addition to the armamentarium of highly effective biologic therapies for psoriasis. In February 2017, the US Food and Drug Administration approved brodalumab for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies [11]. Approval of brodalumab was based upon data from three randomized trials (AMAGINE-1, AMAGINE-2, and AMAGINE-3) that found brodalumab more effective than placebo [12,13]. However, suicidal ideation and behavior occurred in a small number of patients treated with brodalumab. As a result, the drug will only be available in the United States through a Risk Evaluation and Mitigation Strategy program designed to identify patients who develop new or worsening symptoms of depression or suicidality. (See "Treatment of psoriasis", section on 'Brodalumab'.)

Subcutaneous methotrexate for plaque psoriasis (January 2017)

Although methotrexate is a common treatment for psoriasis, data supporting its use are limited. In a randomized trial of 120 patients with moderate to severe plaque psoriasis, those treated with subcutaneous methotrexate for 16 weeks achieved a 75 percent improvement in the Psoriasis Area and Severity Index score more frequently than those receiving placebo (41 versus 10 percent) [14]. Treatment was generally well tolerated. These data support methotrexate as a treatment option for psoriasis. (See "Treatment of psoriasis", section on 'Methotrexate'.)

Haplotype may predict response to tonsillectomy in chronic plaque psoriasis (November 2016)

Tonsillectomy leads to clinical improvement in some patients with chronic plaque psoriasis, although surgery carries risk, and a reliable predictor of which patients are most likely to respond is lacking. A prospective cohort study of 28 patients with moderate to severe chronic plaque psoriasis and a history of psoriasis exacerbations in association with sore throat and/or streptococcal throat infections suggests that HLA-Cw*0602 homozygotes may derive greater benefit from tonsillectomy than HLA-Cw*0602 heterozygotes and HLA-Cw*0602-negative patients [15]. Additional study is necessary to confirm this finding given the small size of the study. (See "Treatment of psoriasis", section on 'Tonsillectomy'.)


Glucocorticoids not necessary for simple acute urticaria (May 2017)

Although patients with urticaria and symptoms involving other organ systems are treated with epinephrine given the likelihood of anaphylaxis, H1 antihistamines are the initial treatment for those with isolated urticaria. For such patients, the additive benefit of glucocorticoids is not well defined. In a randomized trial of 100 adults presenting to the emergency department with isolated urticaria (without angioedema, anaphylaxis, or fever) of ≤24 hours duration, patients received the H1 antihistamine levocetirizine plus either prednisone or placebo for four days [16]. There was no significant difference in the rate of symptom resolution, and most patients were symptom-free within two days. This study supports our suggestion to reserve glucocorticoids for those patients with new urticaria who have prominent angioedema or whose symptoms persist despite antihistamines. (See "New-onset urticaria", section on 'Glucocorticoids'.)


Association of vitiligo with hematopoietic stem cell transplantation (February 2017)

Previous reports suggested that recipients of hematopoietic stem cell transplantation (HSCT) have an increased risk of developing vitiligo. In a Korean nationwide population study including approximately 2700 HSCT recipients and 8200 controls, HSCT recipients had a threefold increased risk of developing vitiligo [17]. Risk factors included receipt of an allogeneic versus autologous graft and stem cells derived from the bone marrow rather than peripheral blood. Although the pathogenetic mechanisms underlying the development of vitiligo in HSCT recipients are unclear, they may include adoptive transfer of vitiligo from donor, immunosuppression associated with preparative regimens, or chronic graft-versus-host disease. Clinicians should counsel patients undergoing HSCT regarding the risk of vitiligo. (See "Vitiligo: Pathogenesis, clinical features, and diagnosis", section on 'Etiology'.)

Topical therapy for pyoderma gangrenosum (November 2016)

Pyoderma gangrenosum (PG) can be challenging to treat and often exhibits prolonged healing times. Topical therapy is commonly used for the treatment of mild PG; however, efficacy data have been limited. In the largest prospective cohort study to assess topical treatments for PG, 66 patients received either clobetasol propionate, tacrolimus, or other topical therapies [18]. The majority of patients (74 percent) received clobetasol propionate. By six months, 44 percent of patients receiving topical therapy achieved ulcer healing. These results provide support for the use of topical therapies. (See "Pyoderma gangrenosum: Treatment and prognosis", section on 'Local corticosteroids'.)

Use of UpToDate is subject to the Subscription and License Agreement.


  1. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med 2016; 375:2335.
  2. (Accessed on April 04, 2017).
  3. Ruzicka T, Hanifin JM, Furue M, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med 2017; 376:826.
  4. (Accessed on December 20, 2016).
  5. Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial. Br J Dermatol 2016; 175:902.
  6. Kim JP, Chao LX, Simpson EL, Silverberg JI. Persistence of atopic dermatitis (AD): A systematic review and meta-analysis. J Am Acad Dermatol 2016; 75:681.
  7. Williams HC, Wojnarowska F, Kirtschig G, et al. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. Lancet 2017; 389:1630.
  8. Trombetta AC, Pizzorni C, Ruaro B, et al. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis. J Rheumatol 2016; 43:2033.
  9. Liu LY, Craiglow BG, Dai F, King BA. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol 2017; 76:22.
  10. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) (2016). (Accessed on November 16, 2016).
  11. (Accessed on February 16, 2017).
  12. Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med 2015; 373:1318.
  13. Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175:273.
  14. Warren RB, Mrowietz U, von Kiedrowski R, et al. An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389:528.
  15. Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B, et al. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series. J Am Acad Dermatol 2016; 75:889.
  16. Barniol C, Dehours E, Mallet J, et al. Levocetirizine and Prednisone Are Not Superior to Levocetirizine Alone for the Treatment of Acute Urticaria: A Randomized Double-Blind Clinical Trial. Ann Emerg Med 2017.
  17. Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea. J Am Acad Dermatol 2017; 76:459.
  18. Thomas KS, Ormerod AD, Craig FE, et al. Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. J Am Acad Dermatol 2016; 75:940.
Topic 87552 Version 7201.0

Topic Outline


All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.